Log In
Print this Print this

rexomun, Ertumaxomab

  Manage Alerts
Collapse Summary General Information
Company Trion Pharma GmbH
DescriptionTrifunctional antibody with specificities for the human epidermal growth factor (EGF) receptor 2 (HER2; ErbB2; neu) and the human CD3 antigen
Molecular Target CD3 ; Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationBreast cancer
Indication DetailsTreat advanced or metastatic breast cancer; Treat metastatic breast cancer progressing after endocrine treatment
Regulatory Designation
PartnerFresenius SE & Co. KGaA

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today